Jin-Chung Shih

Jin-Chung Shih

Auto-generated profile, based on publicly available information

Jin-Chung Shih

Department of Obstetrics and Gynecology, National Taiwan University Hospital, National Taiwan University College of Medicine, Taipei, Taiwan

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 April 2015 in Hepatology
Verified
Journal Article
Open access
PDF file
HCHuey‐Ling Chen
Huey‐Ling Chen
CLChien‐Nan Lee
Chien‐Nan Lee
CCChin‐Hao Chang
Chin‐Hao Chang
YNYen‐Hsuan Ni
Yen‐Hsuan Ni
MSMing‐Kwang Shyu
Ming‐Kwang Shyu
TSTaiwan Study Group for the Prevention of Mother‐to‐Infant Transmission of HBV (PreMIT Study)
Taiwan Study Group for the Prevention of Mother‐to‐Infant Transmission of HBV (PreMIT Study)
The efficacy and safety of maternal tenofovir disoproxil fumarate (TDF) in reducing mother‐to‐infant hepatitis B virus (HBV) transmissions is not clearly understood. We conducted a prospective, multicenter trial and enrolled 118 hepatitis B surface antigen (HBsAg)– and hepatitis B e antigen–positive pregnant women with HBV DNA ≥7.5 log10 IU/mL. The mothers received no medication (control group, n = 56, HBV DNA 8.22 ± 0.39 log10 IU/mL) or TDF 300 mg daily (TDF group, n = 62, HBV DNA 8.18 ± 0.47 log10 IU/mL) from 30‐32 weeks of gestation until 1 month postpartum. Primary outcome was infant HBsAg at 6 months old. At delivery, the TDF group had lower maternal HBV DNA levels (4.29 ± 0.93 versus 8.10 ± 0.56 log10 IU/mL, P < 0.0001). Of the 121/123 newborns, the TDF group had lower rates of HBV DNA positivity at birth (6.15% versus 31.48%, P = 0.0003) and HBsAg positivity at 6 months old (1.54% versus 10.71%, P = 0.0481). Multivariate analysis revealed that the TDF group had lower risk (odds ratio = 0.10, P = 0.0434) and amniocentesis was associated with higher risk (odds ratio 6.82, P = 0.0220) of infant HBsAg positivity. The TDF group had less incidence of maternal alanine aminotransferase (ALT) levels above two times the upper limit of normal for ≥3 months (3.23% versus 14.29%, P = 0.0455), a lesser extent of postpartum elevations of ALT (P = 0.007), and a lower rate of ALT over five times the upper limit of normal (1.64% versus 14.29%, P = 0.0135) at 2 months postpartum. Maternal creatinine and creatinine kinase levels, rates of congenital anomaly, premature birth, and growth parameters in infants were comparable in both groups. At 12 months, one TDF‐group child newly developed HBsAg positivity, presumably due to postnatal infection and inefficient humoral responses to vaccines. Conclusions: Treatment with TDF for highly viremic mothers decreased infant HBV DNA at birth and infant HBsAg positivity at 6 months and ameliorated maternal ALT elevations. (Hepatology 2015;62:375–386

27 January 2009 in Ultrasound in Obstetrics & Gynecology
Verified
Journal Article
Open access
PDF file
JSJ. C. Shih
J. C. Shih
JJJ. M. Palacios Jaraquemada
J. M. Palacios Jaraquemada
YSY. N. Su
Y. N. Su
MSM. K. Shyu
M. K. Shyu
CLC. H. Lin
C. H. Lin
CLC. N. Lee
C. N. Lee
Objective: To assess the role of three‐dimensional (3D) power Doppler in the antenatal diagnosis of placenta accreta and compare its diagnostic performance with gray‐scale and color Doppler ultrasonography.Methods: One hundred and seventy pregnant women with persistent placenta previa totalis (after 28 weeks' gestation) were prospectively enrolled into this study. Gray‐scale transabdominal ultrasound examination was performed to detect loss of the subendometrial echolucent zone and other abnormalities suggestive of placenta accreta. Color flow mapping was used to scan the whole placenta to detect any newly formed vessels at the serosa–bladder border or the presence of abnormal lacunae. Finally a targeted examination of angioarchitecture in the basal and lateral views of the placenta was carried out using 3D power Doppler. The ultrasound findings were analyzed with reference to the final diagnosis made during Cesarean delivery.Results: Placenta accreta and its variants (including increta and percreta) were confirmed in 39 patients at the time of Cesarean delivery. Based on receiver–operating characteristics analysis, ‘numerous coherent vessels’ visualized using 3D power Doppler in the basal view was the best single criterion for the diagnosis of placenta accreta, with a sensitivity of 97% and a specificity of 92%. If we considered the presence of at least one criterion to be diagnostic when using each ultrasound technique, then 3D power Doppler would have the best positive predictive value (76%), followed by gray‐scale (51%) and color Doppler (47%). The majority of patients with placenta accreta showed multiple characteristic features on ultrasound imaging. In contrast, those patients with a false‐positive diagnosis (i.e. the final diagnosis was placenta previa alone) tended to show isolated ultrasound markers of the condition.Conclusion: 3D power Doppler may be useful as a complementary technique for the antenatal diagnosis or exclusion of placenta accreta. Copyright © 2009 ISUOG. Published by John Wiley & Sons, Ltd.

7 February 2012 in BJOG: An International Journal of Obstetrics & Gynaecology
Verified
Journal Article
Closed access
PDF file
CLC‐N Lee
C‐N Lee
SLShin-Yu Lin
Shin-Yu Lin
CLC‐H Lin
C‐H Lin
JSJ‐C Shih
J‐C Shih
TLT‐H Lin
T‐H Lin
YSY‐N Su
Y‐N Su

1 November 2005 in American Journal of Obstetrics and Gynecology
Verified
Journal Article
Closed access
JSJin-Chung Shih
Jin-Chung Shih
KLKao-Lang Liu
Kao-Lang Liu
MSMing-Kwang Shyu
Ming-Kwang Shyu

12 February 2004 in Prenatal Diagnosis
Verified
Journal Article
Closed access
PDF file
MCMing Chen
Ming Chen
GYGuang‐Perng Yeh
Guang‐Perng Yeh
JSJin‐Chung Shih
Jin‐Chung Shih
BWBao‐Tyan Wang
Bao‐Tyan Wang

1 January 2015 in Circulation Journal
Verified
Journal Article
Closed access
CLChun-Wei Lu
Chun-Wei Lu
JSJin-Chung Shih
Jin-Chung Shih
SCSsu-Yuan Chen
Ssu-Yuan Chen
HCHsin-Hui Chiu
Hsin-Hui Chiu
JWJou-Kou Wang
Jou-Kou Wang
MWMei-Hwan Wu
Mei-Hwan Wu
Three risk estimation methods for predicting the cardiac outcomes of pregnancy in women with heart disease have been proposed. This study was designed to compare their prediction performance in an Asian cohort with congenital heart disease (CHD). This study enrolled pregnant women with CHD who delivered their babies after the 20th gestational week between 1985 and 2011. Of 268 pregnancies in 190 women with CHD, 18 (6.7%) had cardiac complications. The incidence of maternal cardiac events among women with a CARPREG index of 0, 1 or 2 was 3.4%, 27.3% and 100%. The incidence was 2.7%, 8.6%, 11.1%, 40% and 17.6% for those with a ZAHARA score 0-0.5, 0.51-1.5, 1.51-2.5, 2.51-3.5 and >3.5. Among patients with a modified World Health Organization (WHO) classification I, II, III and IV, the incidence of maternal cardiac events was 0%, 4.0%, 12.2% and 25.7%. The c-statistic was 0.732 (95% confidence interval (CI): 0.589, 0.876; P<0.001) for the CARPREG score, 0.737 (95% CI: 0.611, 0.864; P=0.001) for the ZAHARA score and 0.827 (95% CI: 0.745, 0.909; P<0.001) for the WHO classification. All 3 risk estimation methods had good performance in predicting maternal cardiac outcomes; however, the modified WHO classification demonstrated superior discrimination and calibration.